Cipla’s arm signs definitive agreements for equity investment in Ethris GmbH
30th Dec 2022

Cipla’s wholly-owned UK subsidiary, Cipla (EU) has signed definitive agreements for equity investment of EUR 15 million in Ethris GmbH (Ethris), a global leader in delivering mRNAs directly to the respiratory system including administration by inhalation.

The investment will facilitate a long-term strategic partnership between Cipla and Ethris for the development of messenger RNA (mRNA)-based therapies and fast-track Cipla’s participation in the mRNA space, enabling it to provide access to cutting-edge solutions developed by Ethris for the developing countries. A collaboration agreement is signed concurrently with the definitive agreement, which paves a path to market Ethris’ innovative portfolio in Cipla’s key emerging markets.

The transaction is expected to get completed within 60 days from the date of signing of the agreement or such other time-period as may be mutually agreed between the parties in writing and shall be subject to completion of necessary regulatory formalities.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.